A citation-based method for searching scientific literature

Wesley Nuffer, Briana Williams, Jennifer M Trujillo. Ther Adv Endocrinol Metab 2019
Times Cited: 5







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.
Emily Brown, Surya P Rajeev, Daniel J Cuthbertson, John P H Wilding. Diabetes Obes Metab 2019
31
20






Canagliflozin review - safety and efficacy profile in patients with T2DM.
Haroon Jakher, Tara I Chang, Marilyn Tan, Kenneth W Mahaffey. Diabetes Metab Syndr Obes 2019
15
20

Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754).
Ronghui Lin, David C Hoerr, Larry E Weaner, Rhys Salter. J Labelled Comp Radiopharm 2017
1
100



An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent.
Sushanta Bhattacharya, Akash Rathore, Deepa Parwani, Chaitali Mallick, Vivek Asati, Shivangi Agarwal, Vaibhav Rajoriya, Ratnesh Das, Sushil Kumar Kashaw. Eur J Med Chem 2020
6
20

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.
Nisa M Maruthur, Eva Tseng, Susan Hutfless, Lisa M Wilson, Catalina Suarez-Cuervo, Zackary Berger, Yue Chu, Emmanuel Iyoha, Jodi B Segal, Shari Bolen. Ann Intern Med 2016
270
20

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Ronnie Aronson, Juan Frias, Allison Goldman, Amanda Darekar, Brett Lauring, Steven G Terra. Diabetes Obes Metab 2018
43
20

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Atsunori Kashiwagi, Satoshi Yoshida, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Hayato Satomi, Yoshinori Kosakai, Kosei Kawamuki. J Diabetes Investig 2016
25
20

Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
81
20

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
65
20

Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.
Peter W F Wilson, Ralph B D'Agostino, Lisa Sullivan, Helen Parise, William B Kannel. Arch Intern Med 2002
20

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
700
20

SGLT inhibitors in management of diabetes.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Lancet Diabetes Endocrinol 2013
161
20

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.
Yutaka Seino, Nobuya Inagaki, Masakazu Haneda, Kohei Kaku, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. J Diabetes Investig 2015
35
20


Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.
Suk Ho Lee, Min Ju Kim, Sung-Han Lee, Jeongmin Kim, Hyun-Ju Park, Jinhwa Lee. Eur J Med Chem 2011
9
20


Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.
Abdullah Kaplan, Emna Abidi, Ahmed El-Yazbi, Ali Eid, George W Booz, Fouad A Zouein. Heart Fail Rev 2018
39
20

Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk.
Vasanti S Malik, Barry M Popkin, George A Bray, Jean-Pierre Després, Frank B Hu. Circulation 2010
848
20

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Yoshihito Ohtake, Tsutomu Sato, Takamitsu Kobayashi, Masahiro Nishimoto, Naoki Taka, Koji Takano, Keisuke Yamamoto, Masayuki Ohmori, Marina Yamaguchi, Kyoko Takami,[...]. J Med Chem 2012
86
20

Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.
Xiaoyu Zhao, Bin Sun, Hongbo Zheng, Jun Liu, Lilin Qian, Xiaoning Wang, Hongxiang Lou. Bioorg Med Chem Lett 2018
6
20

Ertugliflozin: First Global Approval.
Anthony Markham. Drugs 2018
19
20


C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
Yuyang Ding, Liufeng Mao, Dengfeng Xu, Hui Xie, Ling Yang, Hongjiang Xu, Wenjun Geng, Yong Gao, Chunguang Xia, Xiquan Zhang,[...]. Bioorg Med Chem Lett 2015
8
20

Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review.
Subham Das, Anu K R, Sumit Raosaheb Birangal, Ajinkya Nitin Nikam, Abhijeet Pandey, Srinivas Mutalik, Alex Joseph. Life Sci 2020
12
20

Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
Junwon Lee, Jong Yup Kim, Jungsub Choi, Sung-Han Lee, Jeongmin Kim, Jinhwa Lee. Bioorg Med Chem Lett 2010
12
20

Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition.
Wai-Lung Ng, Ho-Chuen Li, Kit-Man Lau, Anthony K N Chan, Clara Bik-San Lau, Tony K M Shing. Sci Rep 2017
3
33

Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Yukio Tanizawa, Kohei Kaku, Eiichi Araki, Kazuyuki Tobe, Yasuo Terauchi, Kazunori Utsunomiya, Yasuhiko Iwamoto, Hirotaka Watada, Wataru Ohtsuka, Daisuke Watanabe,[...]. Expert Opin Pharmacother 2014
62
20

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin Pharmacol Ther 2012
159
20


Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design.
Xuefeng Cao, Wenpeng Zhang, Xu Yan, Zhi Huang, Zhenqing Zhang, Peng Wang, Jie Shen. Bioorg Med Chem Lett 2016
8
20

Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors.
Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Junwon Lee, Sung-Han Lee, Myung Eun Jung, Eun-Jung Son, MinWoo Lee, Jeongmin Kim,[...]. ACS Med Chem Lett 2010
19
20

Active sugar transport in health and disease.
E M Wright, B A Hirayama, D F Loo. J Intern Med 2007
396
20

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm, Susan Huyck, Steven G Terra, James P Mancuso, Samuel S Engel,[...]. Diabetes Ther 2018
58
20

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
551
20

The effect of dapagliflozin on renal function in patients with type 2 diabetes.
Donald Elliott Kohan, Paola Fioretto, Kristina Johnsson, Shamik Parikh, Agata Ptaszynska, Lisa Ying. J Nephrol 2016
45
20

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
149
20

Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Norihisa Nishimura, Mitsuteru Kitade, Ryuichi Noguchi, Tadashi Namisaki, Kei Moriya, Kosuke Takeda, Yasushi Okura, Yosuke Aihara, Akitoshi Douhara, Hideto Kawaratani,[...]. J Gastroenterol 2016
27
20

Identification of a novel Na+/myo-inositol cotransporter.
Michael J Coady, Bernadette Wallendorff, Dominique G Gagnon, Jean-Yves Lapointe. J Biol Chem 2002
114
20

Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger. Diabetes Care 2015
172
20

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
J P H Wilding, E Ferrannini, V A Fonseca, W Wilpshaar, P Dhanjal, A Houzer. Diabetes Obes Metab 2013
91
20

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren, Sabine Pinnetti, Hans J Woerle, Klaus Dugi. Clin Pharmacol Drug Dev 2013
80
20

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Wenhui Zhang, Walter J J Krauwinkel, James Keirns, Robert W Townsend, Kenneth C Lasseter, Lisa Plumb, Takeshi Kadokura, Fumihiko Ushigome, Ronald Smulders. Clin Drug Investig 2013
17
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.